These 2 Coronavirus Stocks Could Soar in the First Half of 2021
Last year, coronavirus vaccine stocks led stock market gains. For instance, Novavax (NASDAQ: NVAX) surged more than 2,000% for the biggest increase among all stocks in all industries. With the pandemic deepening, the priority quickly became disease prevention. The U.S. government even created a program to help speed vaccines to market called Operation Warp Speed.
Companies focusing on coronavirus treatment garnered less attention. Gilead Sciences (NASDAQ: GILD) actually fell 10% last year. That company makes remdesivir, the first FDA-approved treatment for COVID-19. Now that two vaccines have reached the market, though, some investors have shoved treatment-makers aside in favor of the companies that will bring us back to some semblance of normalcy. But as long as people continue to contract COVID-19 in 2021, and if these treatment companies' clinical trial data are positive, their stocks could climb in the New Year.
Image source: Getty Images.
Source Fool.com
